Acute and Delayed Systemic Treatment with Cannabinoid Receptor 2 Agonists to Prevent or Treat/Reverse Osteoporosis in a Mouse Model of SCI
Abstract
The overall goal of this project is to determine whether a selective agonist for the cannabinoid-2 receptor, when systemically delivered, can prevent the onset of osteoporosis in mice when delivered during the acute phase of spinal cord injury or restore bone density when delivery is delayed until the late, chronic period of injury. During this first year, we have focused on aim 1; testing a range of CB2 agonist concentrations, delivered early but over a maximum of 40 days (longest time group). While we are still assessing bone densities (post-mortem), we noted that both the low and high doses of CB2 agonist appear to elicit neuropathic pain-like symptoms, resulting in the required early euthanasia of those subjects. As a result, we are focusing on the mid-range dose for all subsequent experiments. We have also begun Aim 2 by performing the spinal transection surgeries. These animals will require a 3 month period (to induce chronic stage) before initiation of CB2 agonist treatment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2017
- Accession Number
- AD1050249
Entities
People
- Raymond J. Grill
Organizations
- University of Mississippi Medical Center